FRANKFURT Thu Feb 12, 2015 8:54am EST
Feb 12 (Reuters) - Drugmaker Gilead has agreed on a price for its hepatitis C drug Sovaldi of 41,000 euros ($46,625) for a 12-week treatment for Germany's statutory medical insurers, the GKV association of Germany's statutory medical insurers said.
GKV, who provides coverage for about nine out of 10 Germans, said the U.S. biotechnology company had agreed on a price of 43,562.52 euros, which is subject to a 5.88 percent discount for statutory insurers.
The drug had initially been offered in Germany for a list price of 60,000 euros, or about 56,500 euros including the discount. ($1 = 0.8794 euros) (Reporting by Ludwig Burger; Editing by Christoph Steitz)
Related
Gilead Sciences, Inc. Offers Sovaldi For €41,000 In Germany
GKV, who provides coverage for about nine out of 10 Germans, said the U.S. biotechnology company had agreed on a price of 43,562.52 euros, which is subject to a 5.88 percent discount for statutory insurers.
The drug had initially been offered in Germany for a list price of 60,000 euros, or about 56,500 euros including the discount. ($1 = 0.8794 euros) (Reporting by Ludwig Burger; Editing by Christoph Steitz)
Related
Gilead Sciences, Inc. Offers Sovaldi For €41,000 In Germany
How come they pay 460000 and we in America have to pay 86,0000.00? So unfair!!!!!!!!!!!!!
ReplyDelete